Rochester, NY 8/20/2009 11:36:37 PM
World Heart Corp. WHRT - WorldHeart Announces its Levacor Study
World Heart Corp. WHRT
World Heart Corporation announced today that it has received FDA conditional approval to begin a bridge-to-transplant study of the Levacor Ventricular Assist Device at ten US centers. The company is required to provide some additional information to the FDA within 45 days, but the study is permitted to begin upon receipt of clinical center Institutional Review Board approvals.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
"We are extremely pleased to reach this key milestone in the development and clinical implementation of the Levacor VAD," said Mr. J. Alex Martin, WorldHeart's President and CEO. "We are also pleased that the clinical study has been assigned CMS category B2, which makes insurance reimbursement possible. Finally, we believe that our unique assist technology will provide life-saving potential for many heart-failure patients and further advance mechanical circulatory support therapy."
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
